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Background: Response to endocrine therapy in breast cancer correlates with estrogen receptor (ER) and
progesterone receptor (PR) status. Generally, hormone receptor-positive (HR+) breast cancers have favorable
prognosis. In order to understand the exact clinical characteristics and prognosis of single HR-positive breast
cancer (ER + PR- tumors and ER-PR+ tumors), we compared these tumors to double HR+ tumors as well as
HR- negative tumors (ER-PR-).
Methods: We examined the clinical and biological features of 6,980 women with invasive ductal carcinoma,
and these patients were stratified according to ER and PR expression as double HR+ (ER + PR+), single HR+
(ER + PR- and ER-PR+) and double HR-negative (HR-, ER-PR-) tumors.
Results: In this study, 571 (8.2%) cases were single HR+ tumors, of which 90 (1.3%) were ER-PR+ tumors and 481
(6.9%) were ER + PR- tumors. Our multivariate analysis showed that in patients without HER2 overexpression
ER + PR- tumors were associated with an increased risk of recurrence and death compared with ER + PR+
tumors, with a hazard ratio of 2.12 for disease-free survival (DFS) and 4.79 for overall survival (OS). In patients
without HER2 overexpression ER-PR+ tumors had increased risk of recurrence and death compared with ER +
PR+ tumor, with a hazard ratio of 4.19 for DFS and 7.22 for OS. In contrast, in patients with HER2 overexpression,
the difference in survival between single HR+ tumors and double HR+ HR- tumors was not statistically
significant. In patients without HER2 overexpression the DFS and OS of ER + PR- and ER-PR+ tumors
were not significantly different from those of ER-PR- tumors.
Conclusion: We have identified clinically and biologically distinct features of single HR+ tumors (ER–PR+ and
ER + PR–) through comparison with both ER + PR+ and ER-PR- tumors. These differences were only significant in
HER2- tumors, not in HER2+ tumors. Single HR+ tumors without HER2 overexpression (ER + PR-HER2- or ER-PR +
HER2-) were associated with poorer survival than ER + PR + HER2- tumors, and had comparable poor survival to
ER-PR-HER2- tumors (triple-negative breast cancer).
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In breast cancer, steroid hormone receptors (HRs; i.e.,
estrogen receptor [ER] or progesterone receptor [PR])
have been shown to be important prognostic factors
and predictive markers for response to endocrine ther-
apy in the treatment of breast cancer. About 70% of
breast cancers are hormone receptor-positive tumors
(HR+). HR+ breast cancers generally have a favorable
prognosis, but HR-negative (HR-) breast cancers have
a poor prognosis. PR is an estrogen-regulated gene;
ER-positive (ER+) tumors are usually also PR positive
(PR+), whereas ER-negative (ER-) tumors are usually
PR negative (PR-). Therefore, single HR+ (i.e., ER+/PR-
or ER-/PR+) tumors represent a minority of breast
cancers.
Clinical data have shown in both the metastatic and
adjuvant treatment settings that tamoxifen is less effica-
cious in ER + PR− tumors than in ER + PR+ tumors
[1-3], and single HR+ breast cancers, especially ER +
PR- breast cancers, have aggressive features and poorer
prognosis in comparison to double HR+ (ER + PR+)
breast cancer [4,5]. However, to our knowledge, com-
parative studies of HR- (ER-PR-) breast cancers are very
limited [6,7].
Previous studies have shown that ER + PR- tumors ex-
hibit high expression of epidermal growth factor recep-
tors [1,4,7-11], but in most studies, the prognosis of ER
+ PR- tumors was determined without considering hu-
man epidermal growth factor receptor 2 (HER2) expres-
sion. Moreover, these studies had a common limitation,
in that prognosis was evaluated without considering
trastuzumab treatment.
Previous studies have suggested that ER-PR+ tumors
have poorer prognosis than ER + PR+ tumors [10,12-16].
However, due to the rarity of ER-PR+ breast cancer
(a reported incidence of 1.5-3.4% [10,12-15]), the
characteristics and prognosis of this tumor are not
well known.
Therefore, in order to understand the exact clinical
characteristics and prognosis of single HR-positive breast
cancer (ER + PR- tumors and ER-PR+ tumors), we com-
pared these tumors to double HR+ tumors as well as
HR- tumors (ER-PR-), and stratified these results ac-
cording to HER2 overexpression.
Methods
Patients were selected from the clinical database of
the Breast Cancer Center at Samsung Medical Center,
Korea, between January 2003 and July 2013. A total
of 7,010 women with invasive ductal carcinoma were
identified. Of them, 6,980 patients were selected for
this study excluding patients who were diagnosed with bi-
lateral tumors or with distant metastases at preoperative
work-up or underwent neoadjuvant chemotherapy.We reviewed the clinicopathologic characteristics of
patients, including biologic factors, such as ER, PR,
HER2, epidermal growth factor receptors (EGFR), and
Ki-67. The pathologic tumor stage was assessed accord-
ing to the American Joint Committee on Cancer (AJCC)
6th Staging System. For ER and PR staging, nuclear (not
cytoplasmic) staining was scored using the Allred score
(AS) interpretation system, a method that provides
semi-quantitative measurement of the proportion of
positive cells (scored on a 0 to 5 scale) and staining in-
tensity (scored on a 0 to 3 scale), with a maximum score
of 8; an AS > 2 considered positive.
HER2 positivity was defined as an intensity of 3+ by
IHC, a score of 2+ was interpreted as equivocal. A nega-
tive test was defined as staining with a score of 0/1+.
For equivocal stating, silver in situ hybridization (SISH)
or fluorescence in situ hybridization (FISH) were per-
formed; the results were positive for HER2 amplification
when the ratio of HER2 to CEP17 was > 2.2.
For EGFR and/or Ki-67, results were considered posi-
tive based on identification of the following criteria in at
least one core. Immunostaining for EGFR was inter-
preted as positive when at least 10% of the tumor cells
showed moderate to strong membrane staining. Ki-67
was considered positive when ≥ 14.0% of cells showed
staining [17].
Differences in the frequencies of clinicopathological
factors and subtypes were statistically analyzed using the
chi-square test and Fisher’s exact test. Disease-free sur-
vival (DFS) was defined as the time from surgery to the
date of documentation of relapse, including locoregional
recurrence and/or distant metastasis. Overall survival
(OS) was defined as the number of months from surgery
to the date of death. Survival curves were constructed
using the Kaplan-Meier method. Hazard ratios were
estimated using a Cox regression for DFS/OS in a multi-
variate analysis. Statistical significance was defined as
P < 0.05. All statistical analyses were performed using
SPSS Statistics 21.0 (IBM).
Study data were collected using a protocol approved
by the Institutional Review Board of Samsung Medical
Center, Korea (IRB number 2014-09-111). Specific pa-
tient consent was not required because we used retro-
spective data from medical records of patients who had
previously signed information release documents.
Results and discussion
Clinicopathologic characteristics of single hormone
receptor- positive breast cancer
The median follow-up duration for the 6,980 patients in-
cluded in this analysis was 45 months (range, 1-133
months). In this study, 4,651 (66.6%) cases were double
HR+ (ER + PR+) tumors, 1,758 (25.2%) were double
HR- (ER-PR-) tumors, and 571 (8.2%) cases were single
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cases were ER-PR+ tumors and 481 (6.9%) were ER +
PR- tumors. The clinicopathological characteristics of
the four subtypes are summarized in Table 1. Overall,
ER+/PR- tumors were found more frequently in
postmenopausal women (61.5%) than other subtypes
(P < 0.001). Compared with ER + PR+ tumor, ER +
PR- tumors were not significantly different in staging
(P = 0.083), but ER + PR- tumors exhibited higher nuclear
grade (NG,P <0.001), higher Ki-67 level (Ki-67 ≥ 14.0,
76.0% vs. 53.9%, P < 0.001), and higher EGFR and HER2
expression (p < 0.001). However, compared with ER-PR-
tumors, ER + PR- tumors showed lower stage (stage I,
ER + PR- 43.7% vs. ER-PR- 35.8%, P = 0.027), lower NG
(P < 0.001), lower Ki-67 level (P < 0.001), lower p53 expres-
sion (P <0.001) and lower EGFR expression (P < 0.001),
but there was no difference in HER2 overexpression
(P = 0.089).
ER-PR+ tumors had higher NG (P <0.001), higher Ki-67
level (P < 0.001), and higher expression of p53 and EGFR
(P < 0.001) than ER + PR+ tumors. However, compared
with ER-PR- tumors, there was no difference in stage
(P = 0.979) or NG (P = 0.0117). Also, there was no differ-
ence in expression of Ki-67 (P = 0.511), p53 (P = 0.531),
EGFR (P = 0.055) or HER2 (P = 0.419).
Both ER-PR+ and ER + PR- tumors were shown to
have higher HER2 overexpression (34.5%) than ER +
PR+ tumors (11.4%, P < 0.001), but had similar HER2
overexpression to ER-PR- tumors (38.8%, P = 0.192).
The characteristics of single hormone receptor-
positive (ER + PR- and ER-PR+) tumors were more
distinct in HER2-negative (HER2-) tumors than in
HER2 overexpressing (HER2+) tumors. (Additional file 1:
Table S1 and Table S2).
Survival analysis of single hormone receptor- positive
breast cancer
Approximately 97% of patients with ER + PR- tumors
and 88% of patients with ER-PR+ tumors received endo-
crine therapy. More patients with ER + PR- (73.7%) and
ER-PR+ (89.7%) tumors received chemotherapy than the
group with ER + PR+ tumors (68.7%), but less than the
group with ER-PR- tumors (91.9%, Table 1). Approxi-
mately 72% of patients with ER + PR- tumors received
both endocrine therapy and chemotherapy, and 24.9% of
patients received only endocrine therapy. In ER-PR+
tumors, 80% of patients received both chemotherapy
and endocrine therapy, 8.2% of patients received only
endocrine therapy and 9.4% of patients received only
chemotherapy.
With univariate analysis by Kaplan-Meier method, the
survival graph of ER + PR- tumors was located between
that of ER + PR+ tumors and ER-PR- tumors. The 5-year
and 10-year DFS of ER + PR- tumors was 91.4% and79.6%, respectively, and the 5-year and 10-year OS was
95.9% and 93.9%, respectively. Patients with ER-PR+ tu-
mors had worse DFS (5-year 81.0%; 10 year 73.1%) and
OS (5-year 95.3%; 10-year 88.7%, Figure 1) than those with
ER + PR-.
Among 1,376 patients with HER2 overexpression,
there was no significant difference in DFS between four
subgroups (P = 0.529), and patients with ER-PR-HER+
tumors had the worst OS (P = 0.010, Figure 2). However,
the 790 patients who received trastuzumab therapy had
similar OS (P = 0.113), as did the 586 patients who did
not receive trastuzumab therapy (P = 0.147).
In 5,433 patients without HER2 overexpression, ER +
PR- tumors were associated with poorer OS than ER +
PR+ tumors (P < 0.001), but similar OS to ER-PR- tu-
mors (P =0.338). ER-PR+ tumors also had poorer OS
than ER + PR+ tumors (P < 0.001), but there was no
significant difference from the OS of ER-PR- tumors
(P = 0.165, Figure 3).
With multivariate analysis, in patients with HER2
overexpression, the single HR+ (ER + PR- and ER-PR+)
tumors seem to increase risk of recurrence, but this dif-
ference was not significant (Table 2). In patients without
HER2 overexpression, ER + PR- tumors had increased
risk of recurrence and death compared with ER + PR+
tumors, with a hazard ratio of 2.12 (95% CI 1.20 -3.75)
for DFS and 4.79 (95% CI 1.84-12.18) for OS. ER-PR+
tumors were at increased risk of recurrence and death
compared with ER + PR+ tumors, with a hazard ratio of
4.19 (95% CI; 1.86-10.02) for DFS and 7.22 (95% CI
1.62-32.06) for OS (Table 3). ER + PR- tumors and ER-
PR+ tumors were not significantly different in terms of
DFS and OS compared ER-PR- tumors.
Discussion
We have evaluated in detail the biological characteristics
and prognosis of single HR+ tumors through compari-
son with ER + PR+ tumors as well as ER-PR- tumors. In
our series, 8.2% of cases were ER + PR- and 1.4% were
ER-PR+. These numbers are somewhat smaller than
those from previously published series where 10-15% of
cases were ER + PR- and 2-4% were ER-PR+. Most pre-
vious studies included patients with breast cancer
regardless of histologic type, but we analyzed patients
with invasive ductal carcinoma [10,12,13,18]. However,
the clinical and biological features of ER + PR- tumors
were consistent with those found in previous studies,
and there was a high incidence in postmenopausal
women. In terms of NG and IHC of Ki-67 level, p53 and
EGFR, ER + PR- tumors showed moderate characteris-
tics between the levels of ER + PR+ and ER-PR- tumors,
while ER-PR+ tumors were more similar to ER-PR- tumors
than ER + PR+ tumors. In addition, on Kaplan-Meier
analysis, the survival graph of the ER + PR- tumors was
Table 1 Clinicopathologic characteristics of patients with ER + PR+, ER + PR-, ER-PR+ and ER-PR- tumors
ER + PR+ (N = 4651) ER-PR+ (N = 90) ER-PR- (N = 1758) ER + PR- (N = 481)
Age, median (range) 47 (20-90) 48 (22-72) 49 (21-85) 54 (27-84)
Menopause
Postmenopause 1489 (32.4%) 34 38.6% 836 (48.4%) 319 (67.3%)
Premenopause 3110 (67.6%) 54 61.4% 893 (51.6%) 155 (32.7%)
Uknown 52 2 29 7
Operation
MRM 1363 (29.3%) 40 (44.4%) 585 (33.3%) 171 (35.6%)
BCS 3288 (70.7%) 50 (55.6%) 1173 (66.7%) 310 (64.4%)
pT
T1 2985 (64.2%) 49 (54.4%) 860 (48.9%) 286 (59.5%)
T2 1472 (31.6%) 38 (42.2%) 835 (47.5%) 184 (38.3%)
T3 184 (4.0%) 3 (3.3%) 62 (3.5%) 10 (2.1%)
T4 10 (0.2%) 0 (0.0%) 1 (0.1%) 1 (0.2%)
pN
N0 2717 (58.4%) 48 (53.3%) 1105 (62.9%) 303 (63.0%)
N1 1368 (29.4%) 29 (32.2%) 445 (25.3%) 129 (26.8%)
N2 363 (7.8%) 8 (8.9%) 133 (7.6%) 32 (6.7%)
N3 203 (4.4%) 5 (5.6%) 75 (4.3%) 17 (3.5%)
Stage
I 2156 (46.4%) 32 (35.6%) 630 (35.8%) 210 (43.7%)
IIA 1266 (27.2%) 30 (33.3%) 635 (36.1%) 162 (33.7%)
IIB 605 (13.0%) 14 (15.6%) 266 (15.1%) 54 (11.2%)
IIIA 413 (8.9%) 9 (10.0%) 151 (8.6%) 37 (7.7%)
IIIB 8 (0.2%) 0 1 (0.1%) 1 (0.2%)
IIIC 203 (4.4%) 5 (5.6%) 75 (4.3%) 17 (3.5%)
Nuclear Grade
I 974 (21.0%) 1 (1.1%) 12 (0.7%) 67 (14.0%)
II 2656 (57.3%) 26 (29.2%) 358 (20.4%) 206 (43.1%)
III 1006 (21.7%) 62 (69.7%) 1383 (78.9%) 205 (42.9%)
unknown 15 1 5 3
HER2
Positive 518 (11.4%) 30 (34.5%) 671 (38.8%) 159 (34.5%)
Negative 4018 (88.6%) 57 (65.5%) 1058 (61.2%) 302 (65.5%)
Unknown 115 3 29 20
Ki-67
≥ 14.0% 2202 (53.9%) 56 (91.8%) 1334 (93.9%) 292 (76.0%)
< 14.0% 1887 (46.1%) 5 (8.2%) 87 (6.1%) 92 (24.0%)
Unknown 562 29 337 97
p53
Positive 1008 (21.8%) 49 (55.1%) 1021 (58.4%) 162 (34.2%)
Negative 3622 (78.2%) 40 (44.9%) 727 (41.6%) 311 (65.8%)
Unknown 21 1 10 8
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Table 1 Clinicopathologic characteristics of patients with ER + PR+, ER + PR-, ER-PR+ and ER-PR- tumors (Continued)
Chemotherapy
Yes 3127 (68.7%) 78 (89.7%) 1575 (91.9%) 345 (73.7%)
No 1424 (31.3%) 9 (10.3%) 138 (8.1%) 123 (26.3%)
Unknown 100 3 45 13
Radiotherapy
Yes 3543 (78.0%) 55 (64.0%) 1258 (73.8%) 334 (70.9%)
No 1001 (22.0%) 31 (36.0%) 446 (26.2%) 137 (29.1%)
Unknown 107 4 54 10
Endocrine Therapy
Yes 4490 (99.2%) 75 (88.2%) 2 (0.1%) 454 (97.0%)
No 34 (0.8%) 10 (11.8%) 1704 (99.9%) 14 (3.0%)
Unknown 127 5 52 13
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PR- tumors, and ER-PR+ tumors were shown to have
worse survival than ER-PR- tumors.
In previous studies, loss of PR has been suggested to
be a marker of aberrant growth factor signaling and has
been associated with one mechanism for endocrine re-
sistance[11], and several studies have shown that ER +
PR- tumors exhibit high expression of epidermal growth
factor receptors [1,4,7-11]. In our cases, HER2 overex-
pression was 34.5% in single HR+ tumors, and as high
as 38.8% in ER-PR- tumors, but the rate of HER2 over-
expression in ER + PR+ tumors was 11.4%. Therefore,
we stratified our cases according to HER2 overexpres-
sion and we found that differences in clinicopathologic
characteristics were not significantly different between
the four subgroups (ER + PR+, ER-PR+, ER-PR- andFigure 1 (a) Disease-free survival (DFS) and (b) overall survival (OS) oER + PR-) in patients with HER2 overexpression. In
addition, there was no difference in survival between
these four subgroups. However, in patients without
HER2 overexpression, significant differences in biological
characteristics were shown more distinctly; ER + PR-, ER-
PR+ tumors and ER-PR-HER2- tumors (triple-negative
breast cancer, TNBC) were both associated with poor
survival.
As demonstrated in previous studies, PR negativity
may be association with cross talk with epidermal
growth factor receptor- i.e., HER2 or EGFR. In our
study, ER + PR- tumors showed high HER2 overex-
pression. Nevertheless, PR negativity was not a significant
prognostic factor in tumors with HER2 overexpression.
This suggests that HER2 expression may be a more sig-
nificant prognostic factor than PR loss in tumors withf all patients.
Figure 2 (a) Disease-free survival (DFS) and (b) overall survival (OS) of patients with HER2-positive tumors.
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the results of trastuzumab treatment.
However, in tumors without HER2 overexpression,
single HR positivity is a significant prognostic factor.
The survival graph of ER + PR-tumors is between that
of ER + PR+ tumors and ER-PR- tumors initially, but
falls to as poor as TNBC at about the 10-year follow-up.
Therefore, ER + PR-HER2- and TNBC tumors show no
difference in terms of long-term survival. ER-PR +
HER2- tumors show similar biological features to
TNBC, including high Ki-67 level and high expression
of EGFR (about 90%) and p53 (50%). Previous studiesFigure 3 (a) Disease-free survival (DFS) and (b) overall survival (OS) ohave shown incidence rate and clinicopathologic fea-
tures, and ER-PR+ tumors have increased an incidence
in premenopausal women and of an aggressive pheno-
type with higher tumor grade and HER2 overexpres-
sion [10,19,20]. Our results are consistent with those
of previous studies. In our series, although there were
only a few ER-PR + HER2- tumors, approximately 80%
(43/53) of patients with ER-PR +HER2- tumors received
chemotherapy and endocrine therapy. Nevertheless, the
aggressive behavior of these tumors suggests that ER-PR+
tumors are very rare and represent a distinct biological
subtype.f patients with HER2-negative tumors.








DFS ER + PR+ vs. ER-PR+ .391 .619 .399 0.528 1.478 .439 4.973
ER + PR+ vs. ER-PR- .394 .261 2.284 0.131 1.483 .890 2.471
ER + PR+ vs. ER + PR- .457 .388 1.389 0.239 1.580 .738 3.382
ER-PR- vs. ER-PR+ -.003 .619 .000 0.996 .997 .296 3.357
ER-PR- vs. ER + PR- .064 .373 .029 0.864 1.066 .513 2.214
OS ER + PR+ vs. ER-PR+ −7.587 82.200 .009 0.926 .001 .000 4.71E + 66
ER + PR+ vs. ER-PR- 1.376 .583 5.576 0.018 3.958 1.263 12.398
ER + PR+ vs. ER + PR- .241 1.125 .046 0.830 1.273 .140 11.549
ER-PR- vs. ER-PR+ −8.962 82.199 .012 0.913 .000 .000 1.18E + 66
ER-PR- vs. ER + PR- −1.135 1.036 1.200 0.273 .322 .042 2.449
(Adjusted for age, stage, nuclear grade, Ki-67and trastuzumab treatment).
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demonstrating that single HR+ tumors have high expres-
sion of EGFR/HER2 and more aggressive features than
ER + PR+ tumors. However, our results show that single
HR positivity was not a significant prognostic factor in
HER2+ breast cancer. Therefore, the aggressiveness of
single HR+ tumors is not simply due to hyperactive
growth factor signaling pathways. As in recent studies
[7-9], our cases have shown that single HR+ tumors are
associated with a high level of Ki-67 (≥14.0%), and, in
multivariate analysis, Ki-67 was shown to have border-
line significance (P = 0.068). When we additionally ana-
lyzed according to Ki-67 level, in cases with a high level
of Ki-67 (≥14.0%), the differences among the four sub-
types were still shown consistently. However, in patients
with a low Ki-67 level (<14.0%), the prognosis of ER +
PR- tumors was not different from that of ER + PR+ tu-




DFS ER + PR+ vs. ER-PR+ 1.463 .429
ER + PR+ vs. ER-PR- .913 .170
ER + PR+ vs. ER + PR- .753 .291
ER-PR- vs. ER-PR+ .550 .422
ER-PR- vs. ER + PR- -.160 .296
OS ER + PR+ vs. ER-PR+ 1.977 .761
ER + PR+ vs. ER-PR- 1.774 .307
ER + PR+ vs. ER + PR- 1.564 .478
ER-PR- vs. ER-PR+ .203 .728
ER-PR- vs. ER + PR- -.210 .462
(Adjusted for age, stage, nuclear grade and Ki-67).prognostic factor in HR + HER2- tumors with a high
level of Ki-67 expression, but not in HR + HER2+ tu-
mors. These suggest that proliferation-related genes may
be significantly associated with PR negativity. However,
interestingly, ER-PR+ tumors have been shown to have
the worst prognosis of the subtypes, regardless of Ki-67
level, suggesting that ER-PR+ tumors represent a distinct
biological subtype.
This study had several limitations. It was a retrospect-
ive study, and adjuvant treatment was not determined
on a randomized basis. Furthermore, we did not stratify
patients according to treatment with tamoxifen or aro-
matase inhibitors. Although the use of aromatase inhibi-
tors instead of selective estrogen receptor modulators
improved the outcome of ER + PR− patients in the
ATAC trial [21], the BIG 1-98 trial did not demonstrate
a significant benefit of letrozole over tamoxifen in ER +





11.608 0.001 4.319 1.861 10.020
28.982 0.000 2.493 1.788 3.476
6.702 0.010 2.123 1.201 3.755
1.695 0.193 1.733 .757 3.963
.293 0.589 .852 .477 1.523
6.755 0.009 7.220 1.626 32.061
33.488 0.000 5.895 3.232 10.751
10.722 0.001 4.779 1.874 12.189
.078 0.781 1.225 .294 5.105
.207 0.649 .811 .328 2.004
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aromatase inhibitor, excluding patients with contraindi-
cations or adverse effects.
Recent studies have emphasized the influence of PR,
which provides highly significant stratification of ER+
breast cancer into luminal A and B types [7-9]. Prat
et al. proposed that the IHC-based definition of luminal
A tumors is HR+/HER2-/low Ki-67 (less than 14%), and
high PR (more than 20%) [8] and Braun et al. also
defined luminal B tumors by the presence of high-risk
criteria (loss of PR expression or increased proliferation)
[9]. Cancello et al. suggested that PR loss identifies lu-
minal B breast cancer subgroups at higher risk of relapse
and death, both with HER-2+ and HER-2- breast cancer
[7]. The differences observed in HER2+ tumors in our
study may be the result of differences in chemotherapy
and trastuzumab treatment. In that study, about 30% of
patients with ER + PR + HER2+ and ER + PR − HER2+
tumors received endocrine therapy alone, 65–70% re-
ceived chemotherapy plus endocrine therapy as adjuvant
treatments and about 1% in both the ER + PR + HER2+
and ER + PR − HER2+ subgroups received trastuzumab
as an adjuvant therapy[7]. However, in our study, 89% of
patients with HER2 overexpression received chemother-
apy and 57.2% of patients received trastuzumab treatment.
Conclusions
This study has identified clinically and biologically distinct
features of single HR+ tumors (ER + PR- and ER-PR+)
through comparison with both ER + PR+ tumors and
ER-PR- tumors. These differences were significant in
HER2- tumors, but not in HER2+ tumors. ER + PR-
HER2- tumors and ER-PR + HER2- tumors have poorer
survival than ER + PR + HER2- tumors and a similarly
poor survival in comparison to ER-PR-HER2- tumors
(TNBC). Clinical trials in addition to more advanced
biological and molecular studies are necessary to identify
the cause of aggressiveness in single HR+ tumors.
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